<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25074318</article-id><article-id pub-id-type="pmc">4149239</article-id><article-id pub-id-type="publisher-id">110</article-id><article-id pub-id-type="doi">10.1186/s12933-014-0110-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nakamura</surname><given-names>Kazufumi</given-names></name><address><email>ichibun@cc.okayama-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Oe</surname><given-names>Hiroki</given-names></name><address><email>hirokioe@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kihara</surname><given-names>Hajime</given-names></name><address><email>kiharah@potato.hokkai.net</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Shimada</surname><given-names>Kenei</given-names></name><address><email>shimadak@med.osaka-cu.ac.jp</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Fukuda</surname><given-names>Shota</given-names></name><address><email>shota0022@gmail.com</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Kyoko</given-names></name><address><email>kyowa@saiseidr.jp</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Takagi</surname><given-names>Tsutomu</given-names></name><address><email>tcardiol@qb4.so-net.ne.jp</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Yunoki</surname><given-names>Kei</given-names></name><address><email>yunokei@yahoo.co.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Miyoshi</surname><given-names>Toru</given-names></name><address><email>miyoshit@cc.okayama-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hirata</surname><given-names>Kumiko</given-names></name><address><email>hirata8080@gmail.com</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Yoshikawa</surname><given-names>Junichi</given-names></name><address><email>yoshikawaj@n-watanabe-hosp.jp</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ito</surname><given-names>Hiroshi</given-names></name><address><email>itomd@md.okayama-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558 Japan </aff><aff id="Aff2"><label/>Department of Internal Medicine, Kihara Cardiovascular Clinic, Asahikawa, Japan </aff><aff id="Aff3"><label/>Department of Internal Medicine and Cardiology, Osaka City University of Medicine, Osaka, Japan </aff><aff id="Aff4"><label/>Department of Medicine, Osaka Ekisaikai Hospital, Osaka, Japan </aff><aff id="Aff5"><label/>Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan </aff><aff id="Aff6"><label/>Takagi Cardiology Clinic, Kyoto, Japan </aff><aff id="Aff7"><label/>Department of Cardiovascular Medicine, Wakayama Medical University, Wakayama, Japan </aff><aff id="Aff8"><label/>Nishinomiya Watanabe Cardiovascular Center, Nishinomiya, Japan </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>13</volume><elocation-id>110</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Nakamura et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4) inhibitors also attenuate PPH. PPH is one of the factors leading to endothelial dysfunction which is an early event in the pathogenesis of atherosclerosis. Furthermore, DPP-4 inhibitors protect endothelial function through a GLP-1-dependent mechanism. However, the impact of these two types of drugs on endothelial dysfunction in patients with type 2 diabetes has not been fully elucidated. We compared the effects of sitagliptin, a DPP-4 inhibitor, and voglibose, an alpha GI, on endothelial function in patients with diabetes.</p></sec><sec><title>Methods</title><p>We conducted a randomized prospective multicenter study in 66 patients with type 2 diabetes who did not achieve the treatment goal with sulfonylurea, metformin or pioglitazone treatment; 31 patients received sitagliptin treatment and 35 patients, voglibose treatment. The flow-mediated dilatation (FMD) of the brachial artery was measured in the fasting state at baseline and after 12&#x000a0;weeks of treatment. The primary endpoint was a change in FMD (&#x00394;FMD) from the baseline to the end of follow-up. The effects of sitagliptin and voglibose on FMD were assessed by ANCOVA after adjustment for the baseline FMD, age, sex, current smoking, diabetes duration and body mass index. Secondary efficacy measures included changes in HbA1c, GIP, GLP-1, C-peptide, CD34, lipid profile, oxidative stress markers, inflammatory markers and eGFR and any adverse events.</p></sec><sec><title>Results</title><p>&#x00394;FMD was significantly improved after 12&#x000a0;weeks of treatment in both groups, and there was no significant difference in &#x00394;FMD between the two groups. There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups. Compared with voglibose, sitagliptin significantly increased the circulating CD34, a marker of endothelial progenitor cells. Adverse events were observed in 5 patients in only the voglibose group (diarrhea 1, nausea 1, edema 2 and abdominal fullness 1).</p></sec><sec><title>Conclusions</title><p>Sitagliptin improved endothelial dysfunction just as well as voglibose in patients with type 2 diabetes. Sitagliptin had protective effects on endothelial function without adverse events.</p></sec><sec><title>Trial registration</title><p>registered at <ext-link ext-link-type="uri" xlink:href="http://www.umin.ac.jp/ctrj/">http://www.umin.ac.jp/ctrj/</ext-link> under UMIN000003951</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dipeptidyl peptidase 4 (DPP-4) inhibitors</kwd><kwd>Alpha glucosidase inhibitor</kwd><kwd>Endothelial function</kwd><kwd>Flow-mediated dilatation</kwd><kwd>CD34</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Postprandial hyperglycemia (PPH) plays a major role in cardiovascular complications in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR1">1</xref>] and impaired glucose tolerance (IGT) [<xref ref-type="bibr" rid="CR2">2</xref>]. PPH is one of the main factors leading to endothelial dysfunction, which is an early event in the pathogenesis of atherosclerosis [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Alpha glucosidase inhibitor (GI) prevents the digestion of carbohydrates including starch and table sugar, attenuates postprandial hyperglycemia [<xref ref-type="bibr" rid="CR5">5</xref>] and delays the development of type 2 diabetes in patients with IGT [<xref ref-type="bibr" rid="CR6">6</xref>]. Miglitol, an alpha GI, improves endothelial dysfunction assessed by the response of forearm blood flow to reactive hyperemia and flow-mediated dilatation (FMD) in patients with type 2 diabetes and coronary artery disease [<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>]. Acarbose, an alpha GI, improves postprandial endothelial dysfunction in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>] and reduces the risk of cardiovascular events in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR11">11</xref>] and IGT [<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Dipeptidyl peptidase 4 (DPP-4) inhibitor enhances endogenous incretin action and promotes glucose-dependent insulin secretion. Thus, DPP-4 inhibitor attenuates postprandial hyperglycemia [<xref ref-type="bibr" rid="CR14">14</xref>]. Furthermore, glucagon-like peptide-1 (GLP-1), an incretin, induces an endothelial-dependent relaxation via NO-dependent action [<xref ref-type="bibr" rid="CR15">15</xref>] and improves endothelial dysfunction in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR16">16</xref>], and sitagliptin, a DPP-4 inhibitor, protects endothelial function in spontaneously hypertensive rats through a GLP-1-dependent mechanism [<xref ref-type="bibr" rid="CR17">17</xref>]. However, the impact of these two types of drugs on endothelial dysfunction in patients with type 2 diabetes has not been fully elucidated and has been controversial [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>].</p><p>We conducted a randomized prospective multicenter study to compare the effects of sitagliptin, a DPP-4 inhibitor, and voglibose, an alpha GI, on endothelial function assessed by FMD in patients with type 2 diabetes.</p><p>Liao et al. reported that number of circulating endothelial progenitor cells (EPCs) in patients with type 2 diabetes was significantly lower than that in the healthy subjects, treatment with metformin significantly increased EPCs and the EPCs number was related to endothelial function assessed by FMD [<xref ref-type="bibr" rid="CR20">20</xref>]. Fadini et al. reported that sitagliptin increased circulating EPCs in type 2 diabetic patients [<xref ref-type="bibr" rid="CR21">21</xref>]. We also compared the effects of sitagliptin and voglibose on number of circulating EPCs assessed by measurement of CD34, a maker of EPCs [<xref ref-type="bibr" rid="CR22">22</xref>], postive cells in patients with type 2 diabetes in this study.</p><p>DPP-4 inhibitors have anti-inflammatory and anti-oxidative effects [<xref ref-type="bibr" rid="CR23">23</xref>-<xref ref-type="bibr" rid="CR25">25</xref>]. Ishibashi et al. reported that linagliptin inhibited the generation of reactive oxygen species induced by advanced glycation end products (AGEs) in endothelial cells [<xref ref-type="bibr" rid="CR23">23</xref>]. Matsubara et al. reported that sitagliptin improves endothelial dysfunction in association with ant-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes [<xref ref-type="bibr" rid="CR24">24</xref>]. Shiraki et al. reported that GLP-1 reduced TNF-&#x003b1;-induced oxidative stress in endothelial cells [<xref ref-type="bibr" rid="CR25">25</xref>]. We also measured levels of inflammatory markers, including high-sensitivity C-reactive protein (hs-CRP) and pentraxin-3 (PTX-3), and oxidative stress markers, including malondialdehyde-modified low-density lipoprotein (MDA-LDL) and urine 8-hydroxy-2&#x02019;-deoxyguanosine (8-OHdG).</p><p>The primary endpoint in this study was a sitagliptin- or voglibose-induced change in FMD (&#x00394;FMD) from baseline to the end of follow-up. Secondary efficacy measures included changes in HbA1c, gastric inhibitory peptide (GIP), GLP-1, C-peptide, CD34, lipid profile, adiponectin, oxidative stress markers including MDA-LDL and urine 8-OHdG, inflammatory markers including hs-CRP and PTX-3, and estimated glomerular filtration rate (eGFR) and any adverse events.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study populations</title><p>We conducted a randomized prospective multicenter study in patients with type 2 diabetes who did not achieve the treatment goal with diet, exercise, sulfonylurea, metformin or pioglitazone treatment. We recruited 66 patients (men and women) who were from 20 to 85&#x000a0;years of age. Thirty-one patients received the sitagliptin (50&#x000a0;mg/day) treatment and 35 patients, the voglibose (0.6&#x000a0;mg/day) treatment. The doses of the two drugs used in this study are recommended therapeutic doses for Japanese [<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>] and the doses are covered by the Japanese National Health Insurance. The exclusion criteria were as follows: treatment with insulin, alpha GI or glinide, type 1 diabetes, HbA1c&#x02009;&#x02265;&#x02009;9.0%, systolic blood pressure&#x02009;&#x02265;&#x02009;160&#x000a0;mmHg and serum creatinine&#x02009;&#x02265;&#x02009;1.5&#x000a0;mg/dL at baseline. The study protocol was approved by the Ethics Committee of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, and written informed consent was obtained from all patients before any study procedure was undertaken.</p></sec><sec id="Sec4"><title>Study protocol</title><p>The patients were followed for at least 8&#x000a0;weeks to confirm that they did not achieve the treatment goal with diet, exercise, sulfonylurea, metformin or pioglitazone treatment. The patients were prospectively randomly assigned to additional treatment with either sitagliptin (50&#x000a0;mg/day) or voglibose (0.6&#x000a0;mg/day) for 12&#x000a0;weeks (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The flow-mediated dilatation (FMD) of the brachial artery was measured in the fasting state at baseline and after 12&#x000a0;weeks of the treatment. Blood and urine tests were also performed at baseline and at the end of the study. The patients&#x02019; antihypertensive, antihyperlipidemic and antidiabetic drugs were not changed and anti-oxidant drugs, including vitamin C and E, were not added throughout the study period.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Study protocol.</bold> The patients were followed for at least 8&#x000a0;weeks to confirm that they did not achieve the treatment goal. The patients were prospectively, randomly assigned to additional treatment with either sitagliptin (50&#x000a0;mg/day) or voglibose (0.6&#x000a0;mg/day) for 12&#x000a0;weeks. Measurements of flow-mediated dilatation (FMD) of the brachial artery and blood and urine tests were performed in the fasting state at baseline and after 12&#x000a0;weeks of treatment.</p></caption><graphic xlink:href="12933_2014_110_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec5"><title>Measurements of biochemical parameters</title><p>The following parameters were measured at baseline and after 12&#x000a0;weeks of treatment: complete blood count, liver function test including measurement of AST, ALT and LDH, renal function test including measurement of BUN, creatinine, Na, K and Cl, HbA1c, gastric inhibitory peptide (GIP), GLP-1, C-peptide, CD34, lipid profile including total cholesterol, triglyceride, and high-density lipoprotein (HDL-C), adiponectin, oxidative stress markers including MDA-LDL and urine 8-OHdG, inflammatory markers including hs-CRP and PTX-3, and estimated glomerular filtration rate (eGFR). HbA1c levels were measured using high-performance liquid chromatography. The number of CD34+ cells was determined by flow cytometry using FITC-labeled CD45 and phycoerythrin (PE)-labeled CD34 antibodies (BD Biosciences). eGFR (mL/min/1.73&#x000a0;m<sup>2</sup>) was determined by the modified Modification of Diet and Renal Disease study formula (MDRD) for Japanese: eGFR&#x02009;=&#x02009;194&#x02009;&#x000d7;&#x02009;(age<sup>-0.287</sup>)&#x02009;&#x000d7;&#x02009;(serum creatinine<sup>-1.094</sup>)&#x02009;&#x000d7;&#x02009;(0.739 if female) [<xref ref-type="bibr" rid="CR28">28</xref>]. These measurements were performed by SRL Company, Ltd. (Tokyo, Japan).</p></sec><sec id="Sec6"><title>Flow-mediated dilation (FMD)</title><p>Endothelium-dependent dilation was assessed as a parameter of vasodilation according to the guidelines for ultrasound assessment of FMD of the brachial artery in the fasting state [<xref ref-type="bibr" rid="CR29">29</xref>]. Using a 10-MHz linear-array transducer probe (Unex Company Ltd., Nagoya, Japan), longitudinal images of the brachial artery at baseline were recorded with a stereotactic arm, and measurements of the artery diameter were made after supine rest for &#x02265;5&#x000a0;min as previously described [<xref ref-type="bibr" rid="CR30">30</xref>-<xref ref-type="bibr" rid="CR32">32</xref>]. The diameter of the artery was measured from clear anterior (media-adventitia) and posterior (intima-media) interfaces, which were manually determined. Then, suprasystolic compression (50&#x000a0;mmHg higher than systolic blood pressure) was performed at the right forearm for 5&#x000a0;min, and measurements of the artery diameter were made continuously from 30&#x000a0;sec before to &#x02265;2&#x000a0;min after cuff release. Maximum vasodilation was then evaluated from the change in artery diameter after the release of occlusion (%FMD). FMD is known to be affected by a wide range of biological, environmental, and methodological factors [<xref ref-type="bibr" rid="CR33">33</xref>]. To quantify inter- and intra-observer reproducibility, baseline brachial diameter and FMD were measured by three individuals in Okayama University Hospital. Inter- and intra-observer coefficients were high (r&#x02009;&#x0003e;&#x02009;0.90).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>The results are expressed as mean&#x02009;&#x000b1;&#x02009;SD. We assumed that FMD increased by 2% in sitagliptin group and decreased by 0.5% in voglibose group with a standard deviation of 3%. A minimum sample size of 24 participants in each group was required to detect statistical differences in FMD with a power of 80% and &#x003b1; error of 5%. The effects of sitagliptin and voglibose on FMD were assessed by ANCOVA after adjustment for the baseline FMD, age, sex, current smoking, diabetes duration and body mass index (BMI). Differences in age, sex, BMI and abdominal girth were compared using Student&#x02019;s t-test. The duration of diabetes was compared using the Wilcoxon rank sum test and categorical variables, using Fisher&#x02019;s exact test. Differences in secondary efficacy measures between baseline and 12&#x000a0;weeks were compared using the paired Student&#x02019;s t-test. Values of P&#x02009;&#x0003c;&#x02009;0.05 were considered to be statistically significant.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Baseline characteristics</title><p>Although 66 patients with type 2 diabetes were enrolled in this study between September 2010 and December 2011, 6 patients were excluded from this study (4 protocol violation at baseline and 2 withdrawal of consent). During the follow-up period, 5 patients with hypertension dropped out of the study due to change of concomitant antihypertensive drugs. The follow-up study was completed in 55 (83%) of the patients; 24 patients received the sitagliptin treatment and 31 patients, the voglibose treatment. The data collection was completed in July 2012. Baseline characteristics, including age, sex, BMI and the type of anti-diabetic medication are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. It has been reported that endothelium-dependent vasodilation assessed by FMD declines with advance of age [<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>]. We recruited men and women who were from 20 to 85&#x000a0;years of age. The age range was quite wide in our study, but there was no significant difference in age or baseline FMD between the two groups (age, sitagliptin: 66.6&#x02009;&#x000b1;&#x02009;11.9, &#x0003e;70&#x000a0;years: 12, median 69.5, range: 37 &#x02013; 84 versus voglibose: 68.4&#x02009;&#x000b1;&#x02009;9.2, &#x0003e;70&#x000a0;years: 14, median 70.0, range: 48 &#x02013; 80&#x000a0;years old, P&#x02009;=&#x02009;0.529, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) (baseline FMD, sitagliptin: 5.41&#x02009;&#x000b1;&#x02009;2.25 versus voglibose: 4.96&#x02009;&#x000b1;&#x02009;2.16%, P&#x02009;=&#x02009;0.450, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). We did not exclude patients with severe dyslipidemia, but there were no significant differences in use of antihyperlipidemic drugs (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) and baseline total cholesterol, triglyceride and HDL-C (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>) between the two groups. No patients died, developed cardiovascular events or were admitted to the hospital during the course of the study.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Baseline clinical characteristics</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Variables</bold>
</th><th>
<bold>Sitagliptin, n&#x02009;=&#x02009;24</bold>
</th><th>
<bold>Voglibose, n&#x02009;=&#x02009;31</bold>
</th><th>
<bold>P value</bold>
</th></tr></thead><tbody><tr valign="top"><td>Age, y</td><td>66.6&#x02009;&#x000b1;&#x02009;11.9</td><td>68.4&#x02009;&#x000b1;&#x02009;9.2</td><td>0.529</td></tr><tr valign="top"><td>Male</td><td>10 (41.7%)</td><td>18 (58.1%)</td><td>1.000</td></tr><tr valign="top"><td>Diabetes duration, m</td><td>57.6&#x02009;&#x000b1;&#x02009;41.2</td><td>41.9&#x02009;&#x000b1;&#x02009;44.1</td><td>0.075</td></tr><tr valign="top"><td>BMI, kg/m<sup>2</sup>
</td><td>27.8&#x02009;&#x000b1;&#x02009;3.5</td><td>25.7&#x02009;&#x000b1;&#x02009;4.3</td><td>0.061</td></tr><tr valign="top"><td>Abdominal girth, cm</td><td>91.4&#x02009;&#x000b1;&#x02009;11.1</td><td>85.6&#x02009;&#x000b1;&#x02009;17.4</td><td>0.303</td></tr><tr valign="top"><td>Current smoking</td><td>5 (20.8%)</td><td>5 (16.1%)</td><td>0.475</td></tr><tr valign="top"><td>Regular alcohol drinkers</td><td>4 (16.7%)</td><td>9 (29.0%)</td><td>0.349</td></tr><tr valign="top"><td>Diabetic complication</td><td>1 (4.2%)</td><td>2 (6.5%)</td><td>1.000</td></tr><tr valign="top"><td>&#x02003;&#x02009;Diabetic retinopathy</td><td>1 (4.2%)</td><td>0 (0%)</td><td>0.436</td></tr><tr valign="top"><td>&#x02003;&#x02009;Diabetic nephropathy</td><td>0 (0%)</td><td>2 (6.5%)</td><td>0.499</td></tr><tr valign="top"><td>&#x02003;&#x02009;Diabetic neuropathy</td><td>0 (0%)</td><td>0 (0%)</td><td>-</td></tr><tr valign="top"><td>Hypertension</td><td>20 (83.3%)</td><td>25 (80.6%)</td><td>1.000</td></tr><tr valign="top"><td>Hyperlipidemia</td><td>15 (62.5%)</td><td>18 (58.1%)</td><td>0.787</td></tr><tr valign="top"><td>Hyperuricemia</td><td>4 (16.7%)</td><td>2 (6.5%)</td><td>0.387</td></tr><tr valign="top"><td>Renal disturbance</td><td>3 (12.5%)</td><td>2 (3.2%)</td><td>0.307</td></tr><tr valign="top"><td>Established Cardiovascular diseases</td><td>7 (29.2)</td><td>7 (22.6)</td><td>0.756</td></tr><tr valign="top"><td>&#x02003;&#x02009;Cerebrovascular disease</td><td>4 (16.7%)</td><td>1 (3.2%)</td><td>0.156</td></tr><tr valign="top"><td>&#x02003;&#x02009;Myocardial infarction</td><td>3 (12.5%)</td><td>5 (16.1%)</td><td>1.000</td></tr><tr valign="top"><td>&#x02003;&#x02009;Peripheral artery disease</td><td>2 (8.3%)</td><td>1 (3.2%)</td><td>0.575</td></tr><tr valign="top"><td>Antidiabetic drugs</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;Pioglitazone</td><td>11 (45.8)</td><td>16 (51.6%)</td><td>0.787</td></tr><tr valign="top"><td>&#x02003;&#x02009;Sulfonylurea</td><td>5 (20.8%)</td><td>3(9.7%)</td><td>0.276</td></tr><tr valign="top"><td>&#x02003;&#x02009;Metformin</td><td>3 (12.5%)</td><td>0 (0%)</td><td>0.077</td></tr><tr valign="top"><td>Antihypertensive drugs</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;ARB</td><td>15 (62.5%)</td><td>19 (61.3%)</td><td>1.000</td></tr><tr valign="top"><td>&#x02003;&#x02009;CCB</td><td>13 (54.2%)</td><td>18 (58.1%)</td><td>0.791</td></tr><tr valign="top"><td>&#x02003;&#x02009;Diuretics</td><td>9 (37.5%)</td><td>10 (32.3%)</td><td>0.778</td></tr><tr valign="top"><td>&#x02003;&#x02009;Others</td><td>11 (45.8%)</td><td>12 (38.7%)</td><td>0.783</td></tr><tr valign="top"><td>&#x02003;&#x02003;ACE-I</td><td>1 (4.2%)</td><td>3 (9.7%)</td><td/></tr><tr valign="top"><td>&#x02003;&#x02003;&#x003b1;-Blocker</td><td>4 (16.7%)</td><td>3 (9.7%)</td><td/></tr><tr valign="top"><td>&#x02003;&#x02003;&#x003b2;-Blocker</td><td>3 (12.5%)</td><td>5 (16.1%)</td><td/></tr><tr valign="top"><td>&#x02003;&#x02003;&#x003b1;&#x003b2;-Blocker</td><td>1 (4.2%)</td><td>1 (3.2%)</td><td/></tr><tr valign="top"><td>&#x02003;&#x02003;Aldosterone antagonist</td><td>2 (8.3%)</td><td>0 (0%)</td><td/></tr><tr valign="top"><td>Antihyperlipidemic drugs</td><td>2 (8.3%)</td><td>0 (0%)</td><td/></tr><tr valign="top"><td>&#x02003;&#x02009;Statins</td><td>12 (50.0%)</td><td>14 (45.2%)</td><td>0.789</td></tr><tr valign="top"><td>&#x02003;&#x02009;Fibrate</td><td>2 (8.3%)</td><td>2 (6.5%)</td><td>1.000</td></tr><tr valign="top"><td>&#x02003;&#x02009;Ezetimibe</td><td>3 (12.5%)</td><td>6 (19.4%)</td><td>0.716</td></tr><tr valign="top"><td>&#x02003;&#x02009;Eicosapentaenoic acid</td><td>2 (8.3%)</td><td>3 (9.7%)</td><td>1.000</td></tr><tr valign="top"><td>Antithrombogenic agents</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;Antiplatelet agent</td><td>16 (66.7%)</td><td>17 (54.8%)</td><td>0.417</td></tr><tr valign="top"><td>&#x02003;&#x02009;Anticoagulant agent</td><td>2 (8.3%)</td><td>0 (0.0%)</td><td>0.186</td></tr><tr valign="top"><td>Others</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;Nitrates</td><td>3 (12.5%)</td><td>0 (0%)</td><td>0.077</td></tr><tr valign="top"><td>&#x02003;&#x02009;Allopurinol</td><td>1 (4.2%)</td><td>1 (3.2%)</td><td>1.000</td></tr><tr valign="top"><td>&#x02003;&#x02009;Uricosuric agents</td><td>0 (0%)</td><td>1 (3.2%)</td><td>1.000</td></tr></tbody></table><table-wrap-foot><p>ARB: angiotensin receptor blocker, CCB: calcium channel blocker, ACE-I: Angiotensin-converting enzyme inhibitor. Data are expressed as mean&#x02009;&#x000b1;&#x02009;SD or as a number (percentage).</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Changes in FMD (&#x00394;FMD) in the sitagliptin and voglibose group</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="2">
<bold>Variable</bold>
</th><th>
<bold>Sitagliptin</bold>
</th><th>
<bold>Voglibose</bold>
</th><th rowspan="2">
<bold>Between-group difference</bold>
</th></tr><tr valign="top"><th>
<bold>n&#x02009;=&#x02009;24</bold>
</th><th>
<bold>n&#x02009;=&#x02009;31</bold>
</th></tr></thead><tbody><tr valign="top"><td>FMD (%)</td><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;Baseline at 0&#x000a0;W</td><td>5.41&#x02009;&#x000b1;&#x02009;2.25</td><td>4.96&#x02009;&#x000b1;&#x02009;2.16</td><td>P&#x02009;=&#x02009;0.450</td></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>6.17&#x02009;&#x000b1;&#x02009;2.00</td><td>5.94&#x02009;&#x000b1;&#x02009;2.15</td><td>P&#x02009;=&#x02009;0.692</td></tr><tr valign="top"><td>&#x02003;&#x02009;&#x00394;FMD:12&#x000a0;W-0&#x000a0;W</td><td>0.76&#x02009;&#x000b1;&#x02009;2.42</td><td>0.98&#x02009;&#x000b1;&#x02009;2.41</td><td>P&#x02009;=&#x02009;0.729</td></tr><tr valign="top"><td>Adjusted &#x00394;FMD:12&#x000a0;W-0&#x000a0;W*</td><td>1.11</td><td>0.98</td><td rowspan="2">P&#x02009;=&#x02009;0.8316</td></tr><tr valign="top"><td>&#x02003;&#x02009;(95% CIs)</td><td>(0.07-2.16)</td><td>(0.04-1.91)</td></tr></tbody></table><table-wrap-foot><p>Values are means&#x02009;&#x000b1;&#x02009;SD or the least square means (95% CI). *The least square means (95% CIs) were derived from ANCOVA adjusted for the baseline FMD, age, sex, current smoking, diabetes duration and BMI.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Changes in secondary efficacy measures in the sitagliptin and voglibose groups</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th colspan="2">
<bold>Sitagliptin</bold>
</th><th colspan="2">
<bold>Voglibose</bold>
</th><th>
<bold>Between-group difference</bold>
</th></tr><tr valign="top"><th>
<bold>Variable</bold>
</th><th>
<bold>mean&#x02009;&#x000b1;&#x02009;SD</bold>
</th><th>
<bold>P value</bold>
</th><th>
<bold>mean&#x02009;&#x000b1;&#x02009;SD</bold>
</th><th>
<bold>P value</bold>
</th><th>
<bold>P value</bold>
</th></tr></thead><tbody><tr valign="top"><td>HbA1C</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>7.04&#x02009;&#x000b1;&#x02009;0.56</td><td/><td>6.94&#x02009;&#x000b1;&#x02009;0.45</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>6.65&#x02009;&#x000b1;&#x02009;0.57</td><td/><td>6.59&#x02009;&#x000b1;&#x02009;0.45</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;0.39&#x02009;&#x000b1;&#x02009;0.60</td><td>0.0051</td><td>&#x02212;0.35&#x02009;&#x000b1;&#x02009;0.39</td><td>&#x0003c;0.0001</td><td>0.8021</td></tr><tr valign="top"><td>GIP</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>289.92&#x02009;&#x000b1;&#x02009;326.04</td><td/><td>214.21&#x02009;&#x000b1;&#x02009;220.15</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>246.50&#x02009;&#x000b1;&#x02009;284.25</td><td/><td>258.41&#x02009;&#x000b1;&#x02009;226.88</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;43.42&#x02009;&#x000b1;&#x02009;190.10</td><td>0.3077</td><td>44.20&#x02009;&#x000b1;&#x02009;198.54</td><td>0.2671</td><td>0.1323</td></tr><tr valign="top"><td>GLP-1</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>5.71&#x02009;&#x000b1;&#x02009;5.92</td><td/><td>6.65&#x02009;&#x000b1;&#x02009;10.18</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>8.25&#x02009;&#x000b1;&#x02009;6.37</td><td/><td>6.66&#x02009;&#x000b1;&#x02009;6.15</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>2.54&#x02009;&#x000b1;&#x02009;5.71</td><td>0.0611</td><td>0.00&#x02009;&#x000b1;&#x02009;5.70</td><td>0.9973</td><td>0.1418</td></tr><tr valign="top"><td>C-peptide</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>3.913&#x02009;&#x000b1;&#x02009;2.567</td><td/><td>3.037&#x02009;&#x000b1;&#x02009;1.629</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>3.909&#x02009;&#x000b1;&#x02009;2.410</td><td/><td>3.571&#x02009;&#x000b1;&#x02009;2.710</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;0.003&#x02009;&#x000b1;&#x02009;1.366</td><td>0.9906</td><td>0.534&#x02009;&#x000b1;&#x02009;2.712</td><td>0.2977</td><td>0.3555</td></tr><tr valign="top"><td>CD34</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>0.956&#x02009;&#x000b1;&#x02009;0.563</td><td/><td>0.896&#x02009;&#x000b1;&#x02009;0.622</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>1.134&#x02009;&#x000b1;&#x02009;0.615</td><td/><td>0.847&#x02009;&#x000b1;&#x02009;0.470</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>0.178&#x02009;&#x000b1;&#x02009;0.379</td><td>0.0311</td><td>&#x02212;0.050&#x02009;&#x000b1;&#x02009;0.368</td><td>0.4656</td><td>0.0304</td></tr><tr valign="top"><td>Total cholesterol</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>181.6&#x02009;&#x000b1;&#x02009;28.8</td><td/><td>187.8&#x02009;&#x000b1;&#x02009;38.9</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>172.5&#x02009;&#x000b1;&#x02009;28.2</td><td/><td>183.9&#x02009;&#x000b1;&#x02009;46.6</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;9.0&#x02009;&#x000b1;&#x02009;21.5</td><td>0.0509</td><td>&#x02212;3.9&#x02009;&#x000b1;&#x02009;30.0</td><td>0.4865</td><td>0.4807</td></tr><tr valign="top"><td>Triglyceride</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>158.9&#x02009;&#x000b1;&#x02009;131.1</td><td/><td>141.2&#x02009;&#x000b1;&#x02009;68.4</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>122.4&#x02009;&#x000b1;&#x02009;60.9</td><td/><td>119.2&#x02009;&#x000b1;&#x02009;51.9</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;36.5&#x02009;&#x000b1;&#x02009;98.8</td><td>0.0837</td><td>&#x02212;22.1&#x02009;&#x000b1;&#x02009;52.0</td><td>0.0249</td><td>0.5217</td></tr><tr valign="top"><td>HDL-C</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>56.4&#x02009;&#x000b1;&#x02009;16.8</td><td/><td>53.8&#x02009;&#x000b1;&#x02009;13.0</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>57.5&#x02009;&#x000b1;&#x02009;24.4</td><td/><td>50.3&#x02009;&#x000b1;&#x02009;11.4</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>1.0&#x02009;&#x000b1;&#x02009;20.9</td><td>0.8096</td><td>&#x02212;3.5&#x02009;&#x000b1;&#x02009;8.3</td><td>0.0246</td><td>0.3223</td></tr><tr valign="top"><td>adiponectin</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>13.80&#x02009;&#x000b1;&#x02009;12.88</td><td/><td>15.15&#x02009;&#x000b1;&#x02009;13.81</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>13.11&#x02009;&#x000b1;&#x02009;11.10</td><td/><td>14.09&#x02009;&#x000b1;&#x02009;8.76</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;0.69&#x02009;&#x000b1;&#x02009;2.71</td><td>0.2260</td><td>&#x02212;1.06&#x02009;&#x000b1;&#x02009;7.41</td><td>0.4413</td><td>0.8020</td></tr><tr valign="top"><td>MDA-LDL</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>98.7&#x02009;&#x000b1;&#x02009;32.0</td><td/><td>112.4&#x02009;&#x000b1;&#x02009;44.3</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>99.7&#x02009;&#x000b1;&#x02009;44.5</td><td/><td>116.6&#x02009;&#x000b1;&#x02009;49.7</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>1.0&#x02009;&#x000b1;&#x02009;33.8</td><td>0.8812</td><td>4.2&#x02009;&#x000b1;&#x02009;45.0</td><td>0.6156</td><td>0.7787</td></tr><tr valign="top"><td>8-OHdG</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>12.20&#x02009;&#x000b1;&#x02009;6.55</td><td/><td>12.31&#x02009;&#x000b1;&#x02009;8.88</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>13.10&#x02009;&#x000b1;&#x02009;7.39</td><td/><td>12.43&#x02009;&#x000b1;&#x02009;15.46</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>0.90&#x02009;&#x000b1;&#x02009;7.30</td><td>0.5533</td><td>0.12&#x02009;&#x000b1;&#x02009;17.29</td><td>0.9699</td><td>0.8252</td></tr><tr valign="top"><td>hs-CRP</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>2194.4&#x02009;&#x000b1;&#x02009;4079.1</td><td/><td>2052.2&#x02009;&#x000b1;&#x02009;3816.2</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>1202.0&#x02009;&#x000b1;&#x02009;1424.2</td><td/><td>3322.7&#x02009;&#x000b1;&#x02009;7813.6</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;992.4&#x02009;&#x000b1;&#x02009;3609.6</td><td>0.1911</td><td>1270.5&#x02009;&#x000b1;&#x02009;5592.1</td><td>0.2233</td><td>0.0783</td></tr><tr valign="top"><td>PTX-3</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>1.606&#x02009;&#x000b1;&#x02009;0.733</td><td/><td>2.461&#x02009;&#x000b1;&#x02009;2.989</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>1.491&#x02009;&#x000b1;&#x02009;0.585</td><td/><td>1.848&#x02009;&#x000b1;&#x02009;0.790</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;0.115&#x02009;&#x000b1;&#x02009;0.462</td><td>0.2334</td><td>&#x02212;0.613&#x02009;&#x000b1;&#x02009;2.542</td><td>0.1967</td><td>0.3012</td></tr><tr valign="top"><td>e-GFR</td><td/><td/><td/><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;baseline at 0&#x000a0;W</td><td>66.8&#x02009;&#x000b1;&#x02009;20.8</td><td/><td>63.6&#x02009;&#x000b1;&#x02009;20.8</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;at 12&#x000a0;W</td><td>62.2&#x02009;&#x000b1;&#x02009;17.8</td><td/><td>61.4&#x02009;&#x000b1;&#x02009;19.9</td><td/><td/></tr><tr valign="top"><td>&#x02003;&#x02009;12&#x000a0;W-0&#x000a0;W</td><td>&#x02212;4.6&#x02009;&#x000b1;&#x02009;9.7</td><td>0.0301</td><td>&#x02212;2.1&#x02009;&#x000b1;&#x02009;7.7</td><td>0.1306</td><td>0.3007</td></tr></tbody></table><table-wrap-foot><p>GIP: gastric inhibitory peptide, GLP-1: glucagon-like peptide-1, HDL-C: high density lipoprotein cholesterol, MDA-LDL: malondialdehyde-modified low density lipoprotein, 8-OHdG: 8-hydroxy-2&#x02019;-deoxyguanosine, hs-CRP: high-sensitivity C-reactive protein, PTX-3: pentraxin-3, e-GFR: estimated glomerular filtration rate. Data are expressed as mean&#x02009;&#x000b1;&#x02009;SD.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>The primary endpoint</title><p>Change in FMD (&#x00394;FMD) was significantly improved after 12&#x000a0;weeks of treatment in both groups (sitagliptin: +1.11, 95% CI: 0.07-2.16 versus voglibose: +0.98, 95% CI: 0.04-1.91), and there was no significant difference in &#x00394;FMD between the two groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Adjusted changes in FMD (&#x00394;FMD) in the sitagliptin and voglibose groups.</bold> Values are the least square means (95% CI). The least square means (95% CIs) were derived from ANCOVA adjusted for the baseline FMD, age, sex, current smoking, diabetes duration and BMI. &#x00394;FMD was significantly improved after 12&#x000a0;weeks of treatment in both groups, and there was no significant difference in &#x00394;FMD between the two groups.</p></caption><graphic xlink:href="12933_2014_110_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec11"><title>Secondary efficacy measures</title><p>There were no significant differences in changes in HbA1c, GIP, GLP-1, C-peptide, lipid profile, oxidative stress marker, inflammatory marker and eGFR between the two groups (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Sitagliptin tended to increase GLP-1 levels after 12&#x000a0;weeks of treatment (0&#x000a0;week: 5.71&#x02009;&#x000b1;&#x02009;5.92 versus 12&#x000a0;weeks: 8.25&#x02009;&#x000b1;&#x02009;6.37 pmol/L, P&#x02009;=&#x02009;0.0611), but voglibose did not change the levels (0&#x000a0;week: 6.65&#x02009;&#x000b1; 10.18 versus 12&#x000a0;weeks: 6.66&#x02009;&#x000b1;&#x02009;6.15 pmol/L, P&#x02009;=&#x02009;0.9973). Compared with voglibose, sitagliptin significantly increased circulating CD34, a marker of positive endothelial progenitor cells (P&#x02009;&#x0003c;&#x02009;0.05) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Changes in CD34 in the sitagliptin and voglibose groups. A</bold>. Circulating CD34 levels at 0&#x000a0;week and 12&#x000a0;weeks in the sitagliptin and voglibose groups. *P&#x02009;&#x0003c;&#x02009;0.05 vs. 0&#x000a0;W, paired t-test. <bold>B</bold>. Change in CD34 from the baseline to the end of follow-up (&#x00394;CD34). **P&#x02009;&#x0003c;&#x02009;0.05, Student&#x02019;s t-test.</p></caption><graphic xlink:href="12933_2014_110_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec12"><title>Adverse events</title><p>Adverse events were observed in 5 patients in the voglibose group (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). There were no serious side effects in either group.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Adverse events</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Events</bold>
</th><th>
<bold>Sitagliptin</bold>
</th><th>
<bold>Voglibose</bold>
</th></tr><tr valign="top"><th/><th>
<bold>n&#x02009;=&#x02009;29</bold>
</th><th>
<bold>n&#x02009;=&#x02009;34</bold>
</th></tr></thead><tbody><tr valign="top"><td>Diarrhea</td><td>0 (0%)</td><td>1 (2.9%)</td></tr><tr valign="top"><td>Nausea</td><td>0 (0%)</td><td>1 (2.9%)</td></tr><tr valign="top"><td>Edema</td><td>0 (0%)</td><td>2 (5.9%)</td></tr><tr valign="top"><td>Abdominal fullness</td><td>0 (0%)</td><td>1 (2.9%)</td></tr></tbody></table><table-wrap-foot><p>Number of cases (%) is shown.</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>In summary, &#x00394;FMD was significantly improved after 12&#x000a0;weeks of treatment in both the sitagliptin and voglibose groups, and there was no significant difference in &#x00394;FMD between the two groups.</p><p>Alpha GI improves postprandial endothelial dysfunction in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>]. We showed that not only voglibose, an alpha GI, but also sitagliptin, a DPP-4 inhibitor, improves endothelial function as assessed by FMD in patients with type 2 diabetes. The impact of a DPP-4 inhibitor on endothelial dysfunction in patients with type 2 diabetes is controversial. A recent study showed that sitagliptin improved endothelial dysfunction assessed by the reactive hyperemia arterial tonometry index (RHI) after 6&#x000a0;months of treatment in patients with diabetes and coronary artery disease [<xref ref-type="bibr" rid="CR24">24</xref>]. We also showed that sitagliptin improved endothelial dysfunction assessed by another method, FMD. A prospective observational single arm trial also showed that the treatment with sitagliptin for 12&#x000a0;weeks increased FMD in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR36">36</xref>]. Here, we conducted a randomized prospective multicenter study in patients with type 2 diabetes and revealed improvement of FMD after the 12-week treatment with sitagliptin. In contrast, another short-term study showed that DPP-4 inhibitors, including sitagliptin or alogliptin, attenuated endothelial function as evaluated by FMD after 6&#x000a0;weeks of treatment in patients with diabetes [<xref ref-type="bibr" rid="CR19">19</xref>]. Furthermore, voglibose, an alpha GI, did not affect FMD in the study. Therefore, short-term treatment with either DPP-4 inhibitors or alpha GI does not ameliorate endothelial dysfunction in patients with diabetes. Our study showed that 12-week treatment with either sitagliptin or voglibose ameliorated endothelial function. Thus, at least 12&#x000a0;weeks of treatment is needed to improve endothelial function.</p><p>The STOP-NIDDM trial showed that an alpha GI reduces the risk of cardiovascular events in patients with IGT [<xref ref-type="bibr" rid="CR12">12</xref>]. DPP-4 inhibitors are also expected to have beneficial cardiovascular effects [<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref>]. However, two recent trials with DPP-4 inhibitors, SAVOR-TIMI 53 and EXAMINE trials, showed that saxagliptin and alogliptin did not increase or decrease ischemic events in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref>]. These trials demonstrated the safety of DPP-4 inhibitors but did not demonstrate cardiovascular benefits. Patients at high risk patients for cardiovascular disease were enrolled in those studies. In the SAVOR-TIMI 53 trial, about 78% of the patients had established cardiovascular disease, and the EXAMINE trial consisted of patients with acute coronary syndrome. Mean HbA1c levels were about 8.0 in patients of those studies. Our study included relatively low-risk patients. Only about 25% of the patients in our study had established cardiovascular diseases. Mean HbA1c levels were about 7.0. &#x00394;FMD was significantly improved after 12&#x000a0;weeks of treatment in both the sitagliptin and voglibose groups in our study. The clinical implication of this study is the demonstration of beneficial effects of both sitagliptin and voglibose on endothelial dysfunction in low-risk and mild-risk patients with type 2 diabetes. Therefore, sitagliptin and voglibose might have cardiovascular benefits in low-risk and mild-risk patients with type 2 diabetes. Further studies are needed to clarify the long-term benefits for cardiovascular disease [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p>Iwamoto et al. reported that once-daily sitagliptin monotherapy (50&#x000a0;mg/day) showed greater efficacy and better tolerability than did thrice-daily voglibose (0.6&#x000a0;mg/day) over 12&#x000a0;weeks in Japanese patients with type 2 diabetes [<xref ref-type="bibr" rid="CR41">41</xref>], but there was no significant difference in changes in HbA1c between the sitagliptin (50&#x000a0;mg/day) and voglibose (0.6&#x000a0;mg/day) groups in our study. Mean HbA1c levels at baseline in the former study and our study were about 7.8 and 7.0, respectively. Lower HbA1c at baseline in our study might have had an influence on changes in HbA1c levels. Sitagliptin tended to increase GLP-1 levels after 12&#x000a0;weeks of treatment, but there was no significant difference in changes in GIP and GLP-1 between the two groups in this study. These results might be because of the small sample size.</p><p>Matsubara et al. reported that treatment with sitagliptin for 6&#x000a0;months improved endothelial dysfunction along with a decrease in hs-CRP in patients with coronary artery disease and uncontrolled diabetes [<xref ref-type="bibr" rid="CR24">24</xref>]. Lipid profiles and eGFR did not change after treatment with sitagliptin in that study as well as in our study. Our study showed no significant difference in changes in hs-CRP after treatment with sitagliptin. Furthermore, Sakamoto et al. reported that sitagliptin improved blood pressure and lipid profiles in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR42">42</xref>]. These different results might be due to the small sample size, short-term treatment or study in low risk patients with type 2 diabetes.</p><p>Fadini et al. reported that sitagliptin increased circulating EPCs in type 2 diabetic patients with concomitant upregulation of stromal-derived factor-1&#x003b1; (SDF-1&#x003b1;) [<xref ref-type="bibr" rid="CR21">21</xref>]. SDF-1&#x003b1; is a chemokine that stimulates bone marrow mobilization of EPCs and is one of the substrates of DPP-4. We also showed that sitagliptin significantly increased circulating CD34, but voglibose did not increase CD34. Therefore, this is an ancillary effect of sitagliptin and it is independent from blood glucose levels. Liao et al. reported that the number of EPCs was an independent risk factor for FMD [<xref ref-type="bibr" rid="CR20">20</xref>]. Thus, this effect might be favorable for the preservation of endothelial function in the future. Further long-term studies are needed to clarify this point.</p><p>A recent study revealed that alogliptin, a DPP-4 inhibitor, did not increase the frequency of serious adverse events, including hypoglycemia, cancer, pancreatitis, and initiation of dialysis in patients with type 2 diabetes who had a recent acute coronary syndrome [<xref ref-type="bibr" rid="CR40">40</xref>]. A pooled analysis of 25 randomized clinical trials did not indicate that treatment with sitagliptin increases cardiovascular risk in patients with type 2 diabetes mellitus [<xref ref-type="bibr" rid="CR43">43</xref>]. Our study also showed that sitagliptin did not cause serious adverse events. Thus, DPP-4 inhibitors may be safe drugs for patients with type 2 diabetes.</p><sec id="Sec14"><title>Study limitations</title><p>The first limitation of this study was the small sizes of the groups. The second was heterogeneity of the population in this study. The age range was quite wide in our study. The third limitation was that our study was a short-term study. Our findings need to be confirmed in a large cohort of patients with type 2 diabetes and with a long period.</p><p>In conclusion, sitagliptin improves endothelial dysfunction just as well as voglibose in patients with type 2 diabetes. Furthermore, sitagliptin increases the level of circulating CD34. Sitagliptin has protective effects on endothelial function without adverse events. These effects have potential favorable cardiovascular implications for patients with type 2 diabetes.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>BMI</term><def><p>Body mass index</p></def></def-item><def-item><term>DPP-4</term><def><p>Dipeptidyl peptidase IV</p></def></def-item><def-item><term>eGFR</term><def><p>Estimated glomerular filtration rate</p></def></def-item><def-item><term>FMD</term><def><p>Flow-mediated dilatation</p></def></def-item><def-item><term>GIP</term><def><p>Gastric inhibitory peptide</p></def></def-item><def-item><term>GLP-1</term><def><p>Glucagon-like peptide-1</p></def></def-item><def-item><term>GI</term><def><p>Glucosidase inhibitor</p></def></def-item><def-item><term>hs-CRP</term><def><p>High-sensitivity C-reactive protein</p></def></def-item><def-item><term>8-OHdG</term><def><p>8-hydroxy-2&#x02019;-deoxyguanosine</p></def></def-item><def-item><term>IGT</term><def><p>Impaired glucose tolerance</p></def></def-item><def-item><term>MDA-LDL</term><def><p>Malondialdehyde-modified low density lipoprotein</p></def></def-item><def-item><term>PTX-3</term><def><p>Pentraxin-3</p></def></def-item><def-item><term>PPH</term><def><p>Postprandial hyperglycemia</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>KN, YJ, HI conceived the study, and participated in its design and coordination and helped to draft the manuscript. KN, HO, HK, KS, SF, KW, TT, KY, TM, KH carried out examinations. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was supported by Osaka Foundation for the prevention of cancer and cardiovascular diseases. The authors also thank the EDGE study investigators: Kazufumi Nakamura, MD; Hiroki Oe, MD; Kei Yunoki, MD; Toru Miyoshi, MD, Hiroshi Ito, MD (Okayama University, Okayama, Japan), Hajime Kihara, MD (Kihara Cardiovascular Clinic), Kenei Shimada, MD (Osaka City University of Medicine), Shota Fukuda, MD (Osaka Ekisaikai Hospital), Kyoko Watanabe, MD (Okayama Saiseikai Hospital), Tsutomu Takagi, MD (Takagi Cardiology Clinic), Kumiko Hirata, MD (Wakayama Medical University) and Junichi Yoshikawa, MD (Nishinomiya Watanabe Cardiovascular Center).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>S</given-names></name><name><surname>Julius</surname><given-names>U</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Schwanebeck</surname><given-names>U</given-names></name><name><surname>Schmechel</surname><given-names>H</given-names></name><name><surname>Ziegelasch</surname><given-names>HJ</given-names></name><name><surname>Lindner</surname><given-names>J</given-names></name></person-group><article-title>Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up</article-title><source>Diabetologia</source><year>1996</year><volume>39</volume><issue>12</issue><fpage>1577</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1007/s001250050617</pub-id><pub-id pub-id-type="pmid">8960845</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>DECODE-Study-Group</collab></person-group><article-title>Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><issue>3</issue><fpage>688</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.3.688</pub-id><pub-id pub-id-type="pmid">12610023</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>H</given-names></name><name><surname>Motoyama</surname><given-names>T</given-names></name><name><surname>Hirashima</surname><given-names>O</given-names></name><name><surname>Hirai</surname><given-names>N</given-names></name><name><surname>Miyao</surname><given-names>Y</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Kugiyama</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Yasue</surname><given-names>H</given-names></name></person-group><article-title>Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery</article-title><source>J Am Coll Cardiol</source><year>1999</year><volume>34</volume><issue>1</issue><fpage>146</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(99)00168-0</pub-id><pub-id pub-id-type="pmid">10400004</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wascher</surname><given-names>TC</given-names></name><name><surname>Schmoelzer</surname><given-names>I</given-names></name><name><surname>Wiegratz</surname><given-names>A</given-names></name><name><surname>Stuehlinger</surname><given-names>M</given-names></name><name><surname>Mueller-Wieland</surname><given-names>D</given-names></name><name><surname>Kotzka</surname><given-names>J</given-names></name><name><surname>Enderle</surname><given-names>M</given-names></name></person-group><article-title>Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance</article-title><source>Eur J Clin Invest</source><year>2005</year><volume>35</volume><issue>9</issue><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.2005.01550.x</pub-id><pub-id pub-id-type="pmid">16128861</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>AE</given-names></name><name><surname>Montgomery</surname><given-names>PA</given-names></name></person-group><article-title>Acarbose: an alpha-glucosidase inhibitor</article-title><source>Am J Health Syst Pharm</source><year>1996</year><volume>53</volume><issue>19</issue><fpage>2277</fpage><lpage>2290</lpage><pub-id pub-id-type="pmid">8893066</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiasson</surname><given-names>JL</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Gomis</surname><given-names>R</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Karasik</surname><given-names>A</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name></person-group><article-title>Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><issue>9323</issue><fpage>2072</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)08905-5</pub-id><pub-id pub-id-type="pmid">12086760</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiki</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Kiyanagi</surname><given-names>T</given-names></name><name><surname>Fukao</surname><given-names>K</given-names></name><name><surname>Hirose</surname><given-names>K</given-names></name><name><surname>Ohsaka</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>Y</given-names></name><name><surname>Kume</surname><given-names>A</given-names></name><name><surname>Matsumori</surname><given-names>R</given-names></name><name><surname>Sumiyoshi</surname><given-names>K</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Ohmura</surname><given-names>H</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Miida</surname><given-names>T</given-names></name><name><surname>Daida</surname><given-names>H</given-names></name></person-group><article-title>Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH)</article-title><source>Circ J</source><year>2010</year><volume>74</volume><issue>7</issue><fpage>1471</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-10-0013</pub-id><pub-id pub-id-type="pmid">20519875</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emoto</surname><given-names>T</given-names></name><name><surname>Sawada</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Kageyama</surname><given-names>H</given-names></name><name><surname>Terashita</surname><given-names>D</given-names></name><name><surname>Mizoguchi</surname><given-names>T</given-names></name><name><surname>Mizuguchi</surname><given-names>T</given-names></name><name><surname>Motodi</surname><given-names>Y</given-names></name><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Taira</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Matsuo</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Takarada</surname><given-names>A</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name></person-group><article-title>Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease</article-title><source>Am J Cardiol</source><year>2012</year><volume>109</volume><issue>1</issue><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2011.08.005</pub-id><pub-id pub-id-type="pmid">21944671</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimabukuro</surname><given-names>M</given-names></name><name><surname>Higa</surname><given-names>N</given-names></name><name><surname>Chinen</surname><given-names>I</given-names></name><name><surname>Yamakawa</surname><given-names>K</given-names></name><name><surname>Takasu</surname><given-names>N</given-names></name></person-group><article-title>Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><issue>3</issue><fpage>837</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1210/jc.2005-1566</pub-id><pub-id pub-id-type="pmid">16368744</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Node</surname><given-names>K</given-names></name></person-group><article-title>Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study</article-title><source>Cardiovasc Diabetol</source><year>2010</year><volume>9</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-9-12</pub-id><pub-id pub-id-type="pmid">20334663</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Cagatay</surname><given-names>M</given-names></name><name><surname>Petrowitsch</surname><given-names>T</given-names></name><name><surname>Neuser</surname><given-names>D</given-names></name><name><surname>Petzinna</surname><given-names>D</given-names></name><name><surname>Rupp</surname><given-names>M</given-names></name></person-group><article-title>Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies</article-title><source>Eur Heart J</source><year>2004</year><volume>25</volume><issue>1</issue><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0195-668X(03)00468-8</pub-id><pub-id pub-id-type="pmid">14683737</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiasson</surname><given-names>JL</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Gomis</surname><given-names>R</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Karasik</surname><given-names>A</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name></person-group><article-title>Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial</article-title><source>JAMA</source><year>2003</year><volume>290</volume><issue>4</issue><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1001/jama.290.4.486</pub-id><pub-id pub-id-type="pmid">12876091</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Schaper</surname><given-names>F</given-names></name><name><surname>Koehler</surname><given-names>C</given-names></name></person-group><article-title>Effect of acarbose on vascular disease in patients with abnormal glucose tolerance</article-title><source>Cardiovasc Drugs Ther</source><year>2008</year><volume>22</volume><issue>3</issue><fpage>225</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1007/s10557-008-6091-1</pub-id><pub-id pub-id-type="pmid">18309462</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>C</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>R</given-names></name><name><surname>Tsujino</surname><given-names>D</given-names></name><name><surname>Ando</surname><given-names>K</given-names></name><name><surname>Morimoto</surname><given-names>A</given-names></name><name><surname>Utsunomiya</surname><given-names>K</given-names></name></person-group><article-title>Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study</article-title><source>Diabetes Technol Ther</source><year>2013</year><volume>15</volume><issue>5</issue><fpage>378</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1089/dia.2012.0262</pub-id><pub-id pub-id-type="pmid">23634671</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anagnostis</surname><given-names>P</given-names></name><name><surname>Athyros</surname><given-names>VG</given-names></name><name><surname>Adamidou</surname><given-names>F</given-names></name><name><surname>Panagiotou</surname><given-names>A</given-names></name><name><surname>Kita</surname><given-names>M</given-names></name><name><surname>Karagiannis</surname><given-names>A</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name></person-group><article-title>Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control</article-title><source>Diabetes Obes Metab</source><year>2011</year><volume>13</volume><issue>4</issue><fpage>302</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01345.x</pub-id><pub-id pub-id-type="pmid">21205117</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nystrom</surname><given-names>T</given-names></name><name><surname>Gutniak</surname><given-names>MK</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Ahren</surname><given-names>B</given-names></name><name><surname>Sjoholm</surname><given-names>A</given-names></name></person-group><article-title>Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease</article-title><source>Am J Physiol Endocrinol Metab</source><year>2004</year><volume>287</volume><issue>6</issue><fpage>E1209</fpage><lpage>E1215</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00237.2004</pub-id><pub-id pub-id-type="pmid">15353407</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>WT</given-names></name><name><surname>Tian</surname><given-names>XY</given-names></name><name><surname>Lau</surname><given-names>CW</given-names></name><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Lam</surname><given-names>KS</given-names></name><name><surname>Chen</surname><given-names>ZY</given-names></name><name><surname>Ng</surname><given-names>CF</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism</article-title><source>Hypertension</source><year>2012</year><volume>60</volume><issue>3</issue><fpage>833</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.112.195115</pub-id><pub-id pub-id-type="pmid">22868389</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pistrosch</surname><given-names>F</given-names></name><name><surname>Schaper</surname><given-names>F</given-names></name><name><surname>Passauer</surname><given-names>J</given-names></name><name><surname>Koehler</surname><given-names>C</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name></person-group><article-title>Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes</article-title><source>Horm Metab Res</source><year>2009</year><volume>41</volume><issue>2</issue><fpage>104</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1103276</pub-id><pub-id pub-id-type="pmid">19061152</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayaori</surname><given-names>M</given-names></name><name><surname>Iwakami</surname><given-names>N</given-names></name><name><surname>Uto-Kondo</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Iizuka</surname><given-names>M</given-names></name><name><surname>Takiguchi</surname><given-names>S</given-names></name><name><surname>Yakushiji</surname><given-names>E</given-names></name><name><surname>Nakaya</surname><given-names>K</given-names></name><name><surname>Yogo</surname><given-names>M</given-names></name><name><surname>Ogura</surname><given-names>M</given-names></name><name><surname>Takase</surname><given-names>B</given-names></name><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Ikewaki</surname><given-names>K</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients</article-title><source>J Am Heart Assoc</source><year>2013</year><volume>2</volume><issue>1</issue><fpage>e003277</fpage><pub-id pub-id-type="doi">10.1161/JAHA.112.003277</pub-id><pub-id pub-id-type="pmid">23525426</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>YF</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Zeng</surname><given-names>TS</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>LJ</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name></person-group><article-title>Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes</article-title><source>Vasc Med</source><year>2010</year><volume>15</volume><issue>4</issue><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1177/1358863X10367537</pub-id><pub-id pub-id-type="pmid">20511292</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Boscaro</surname><given-names>E</given-names></name><name><surname>Albiero</surname><given-names>M</given-names></name><name><surname>Menegazzo</surname><given-names>L</given-names></name><name><surname>Frison</surname><given-names>V</given-names></name><name><surname>de Kreutzenberg</surname><given-names>S</given-names></name><name><surname>Agostini</surname><given-names>C</given-names></name><name><surname>Tiengo</surname><given-names>A</given-names></name><name><surname>Avogaro</surname><given-names>A</given-names></name></person-group><article-title>The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>7</issue><fpage>1607</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.2337/dc10-0187</pub-id><pub-id pub-id-type="pmid">20357375</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname><given-names>AR</given-names></name><name><surname>Losordo</surname><given-names>DW</given-names></name></person-group><article-title>CD34-positive stem cells: in the treatment of heart and vascular disease in human beings</article-title><source>Tex Heart Inst J</source><year>2011</year><volume>38</volume><issue>5</issue><fpage>474</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">22163120</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>Y</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Higashimoto</surname><given-names>Y</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name></person-group><article-title>Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><fpage>125</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-125</pub-id><pub-id pub-id-type="pmid">23984879</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>J</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Akiyama</surname><given-names>E</given-names></name><name><surname>Iwashita</surname><given-names>S</given-names></name><name><surname>Kurokawa</surname><given-names>H</given-names></name><name><surname>Ohba</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Fujisue</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>E</given-names></name><name><surname>Kaikita</surname><given-names>K</given-names></name><name><surname>Hokimoto</surname><given-names>S</given-names></name><name><surname>Jinnouchi</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes</article-title><source>Circ J</source><year>2013</year><volume>77</volume><issue>5</issue><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-12-1168</pub-id><pub-id pub-id-type="pmid">23386232</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiraki</surname><given-names>A</given-names></name><name><surname>Oyama</surname><given-names>J</given-names></name><name><surname>Komoda</surname><given-names>H</given-names></name><name><surname>Asaka</surname><given-names>M</given-names></name><name><surname>Komatsu</surname><given-names>A</given-names></name><name><surname>Sakuma</surname><given-names>M</given-names></name><name><surname>Kodama</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Kotooka</surname><given-names>N</given-names></name><name><surname>Hirase</surname><given-names>T</given-names></name><name><surname>Node</surname><given-names>K</given-names></name></person-group><article-title>The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells</article-title><source>Atherosclerosis</source><year>2012</year><volume>221</volume><issue>2</issue><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.12.039</pub-id><pub-id pub-id-type="pmid">22284365</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Nonaka</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>T</given-names></name><name><surname>Okuyama</surname><given-names>K</given-names></name><name><surname>Arjona Ferreira</surname><given-names>JC</given-names></name><name><surname>Amatruda</surname><given-names>J</given-names></name></person-group><article-title>Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus</article-title><source>Endocr J</source><year>2010</year><volume>57</volume><issue>5</issue><fpage>383</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K09E-272</pub-id><pub-id pub-id-type="pmid">20332588</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Miyake</surname><given-names>S</given-names></name><name><surname>Ueki</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>Y</given-names></name><name><surname>Akazawa</surname><given-names>S</given-names></name><name><surname>Tominaga</surname><given-names>Y</given-names></name></person-group><article-title>Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><issue>2</issue><fpage>256</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.2337/diacare.21.2.256</pub-id><pub-id pub-id-type="pmid">9539992</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>E</given-names></name><name><surname>Horio</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>K</given-names></name><name><surname>Nitta</surname><given-names>K</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Hishida</surname><given-names>A</given-names></name></person-group><article-title>Revised equations for estimated GFR from serum creatinine in Japan</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><issue>6</issue><fpage>982</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.12.034</pub-id><pub-id pub-id-type="pmid">19339088</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corretti</surname><given-names>MC</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Celermajer</surname><given-names>D</given-names></name><name><surname>Charbonneau</surname><given-names>F</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><name><surname>Deanfield</surname><given-names>J</given-names></name><name><surname>Drexler</surname><given-names>H</given-names></name><name><surname>Gerhard-Herman</surname><given-names>M</given-names></name><name><surname>Herrington</surname><given-names>D</given-names></name><name><surname>Vallance</surname><given-names>P</given-names></name><name><surname>Vita</surname><given-names>J</given-names></name><name><surname>Vogel</surname><given-names>R</given-names></name></person-group><article-title>Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>39</volume><issue>2</issue><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(01)01746-6</pub-id><pub-id pub-id-type="pmid">11788217</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunoki</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Miyoshi</surname><given-names>T</given-names></name><name><surname>Enko</surname><given-names>K</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Kusano</surname><given-names>KF</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group><article-title>Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction</article-title><source>Atherosclerosis</source><year>2011</year><volume>217</volume><issue>2</issue><fpage>486</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.04.019</pub-id><pub-id pub-id-type="pmid">21592480</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunoki</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Miyoshi</surname><given-names>T</given-names></name><name><surname>Enko</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Hata</surname><given-names>Y</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Kusano</surname><given-names>KF</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group><article-title>Impact of hypertriglyceridemia on endothelial dysfunction during statin +/&#x02212;ezetimibe therapy in patients with coronary heart disease</article-title><source>Am J Cardiol</source><year>2011</year><volume>108</volume><issue>3</issue><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2011.03.049</pub-id><pub-id pub-id-type="pmid">21545981</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>Y</given-names></name><name><surname>Miyoshi</surname><given-names>T</given-names></name><name><surname>Oe</surname><given-names>H</given-names></name><name><surname>Ohno</surname><given-names>Y</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Toh</surname><given-names>N</given-names></name><name><surname>Kohno</surname><given-names>K</given-names></name><name><surname>Morita</surname><given-names>H</given-names></name><name><surname>Kusano</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name></person-group><article-title>Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-8</pub-id><pub-id pub-id-type="pmid">23298374</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charakida</surname><given-names>M</given-names></name><name><surname>de Groot</surname><given-names>E</given-names></name><name><surname>Loukogeorgakis</surname><given-names>SP</given-names></name><name><surname>Khan</surname><given-names>T</given-names></name><name><surname>Luscher</surname><given-names>T</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Deanfield</surname><given-names>JE</given-names></name></person-group><article-title>Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>45</issue><fpage>3501</fpage><lpage>3507</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht223</pub-id><pub-id pub-id-type="pmid">23821401</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>L</given-names></name></person-group><article-title>Impact of ageing on the measurement of endothelium-dependent vasodilation</article-title><source>Pharmacol Rep</source><year>2006</year><volume>58</volume><issue>Suppl</issue><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17332670</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruhashi</surname><given-names>T</given-names></name><name><surname>Soga</surname><given-names>J</given-names></name><name><surname>Fujimura</surname><given-names>N</given-names></name><name><surname>Idei</surname><given-names>N</given-names></name><name><surname>Mikami</surname><given-names>S</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Kajikawa</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>Kihara</surname><given-names>Y</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><name><surname>Noma</surname><given-names>K</given-names></name><name><surname>Nakashima</surname><given-names>A</given-names></name><name><surname>Goto</surname><given-names>C</given-names></name><name><surname>Tomiyama</surname><given-names>H</given-names></name><name><surname>Takase</surname><given-names>B</given-names></name><name><surname>Yamashina</surname><given-names>A</given-names></name><name><surname>Higashi</surname><given-names>Y</given-names></name></person-group><article-title>Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study</article-title><source>Heart</source><year>2013</year><volume>99</volume><issue>24</issue><fpage>1837</fpage><lpage>1842</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2013-304739</pub-id><pub-id pub-id-type="pmid">24153417</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Takagi</surname><given-names>G</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Kirinoki-Ichikawa</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name></person-group><article-title>The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes</article-title><source>J Korean Med Sci</source><year>2012</year><volume>27</volume><issue>11</issue><fpage>1364</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.3346/jkms.2012.27.11.1364</pub-id><pub-id pub-id-type="pmid">23166419</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ</given-names></name></person-group><article-title>Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes</article-title><source>Postgrad Med</source><year>2013</year><volume>125</volume><issue>3</issue><fpage>7</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.3810/pgm.2013.05.2659</pub-id><pub-id pub-id-type="pmid">23748503</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Whittington</surname><given-names>HJ</given-names></name><name><surname>Wynne</surname><given-names>AM</given-names></name><name><surname>Begum</surname><given-names>SS</given-names></name><name><surname>Theodorou</surname><given-names>L</given-names></name><name><surname>Riksen</surname><given-names>N</given-names></name><name><surname>Mocanu</surname><given-names>MM</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><issue>1</issue><fpage>154</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-154</pub-id><pub-id pub-id-type="pmid">24148218</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Hirshberg</surname><given-names>B</given-names></name><name><surname>Ohman</surname><given-names>P</given-names></name><name><surname>Frederich</surname><given-names>R</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Hoffman</surname><given-names>EB</given-names></name><name><surname>Cavender</surname><given-names>MA</given-names></name><name><surname>Udell</surname><given-names>JA</given-names></name><name><surname>Desai</surname><given-names>NR</given-names></name><name><surname>Mosenzon</surname><given-names>O</given-names></name><name><surname>McGuire</surname><given-names>DK</given-names></name><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Leiter</surname><given-names>LA</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name></person-group><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1317</fpage><lpage>1326</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307684</pub-id><pub-id pub-id-type="pmid">23992601</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Heller</surname><given-names>SR</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Perez</surname><given-names>AT</given-names></name><name><surname>Fleck</surname><given-names>PR</given-names></name><name><surname>Mehta</surname><given-names>CR</given-names></name><name><surname>Kupfer</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Zannad</surname><given-names>F</given-names></name></person-group><article-title>Alogliptin after acute coronary syndrome in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1305889</pub-id><pub-id pub-id-type="pmid">23992602</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Nonaka</surname><given-names>K</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Nishii</surname><given-names>M</given-names></name><name><surname>Arjona Ferreira</surname><given-names>JC</given-names></name><name><surname>Amatruda</surname><given-names>JM</given-names></name></person-group><article-title>Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial</article-title><source>Diabetes Obes Metab</source><year>2010</year><volume>12</volume><issue>7</issue><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2010.01197.x</pub-id><pub-id pub-id-type="pmid">20590736</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>J</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Kuroki</surname><given-names>S</given-names></name><name><surname>Gondo</surname><given-names>S</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Kodama</surname><given-names>K</given-names></name><name><surname>Hiwatashi</surname><given-names>A</given-names></name><name><surname>Shimomura</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>I</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Node</surname><given-names>K</given-names></name></person-group><article-title>Effects of sitagliptin beyond glycemic control: focus on quality of life</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-35</pub-id><pub-id pub-id-type="pmid">23432786</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engel</surname><given-names>SS</given-names></name><name><surname>Golm</surname><given-names>GT</given-names></name><name><surname>Shapiro</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Kaufman</surname><given-names>KD</given-names></name><name><surname>Goldstein</surname><given-names>BJ</given-names></name></person-group><article-title>Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis</article-title><source>Cardiovasc Diabetol</source><year>2013</year><volume>12</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-3</pub-id><pub-id pub-id-type="pmid">23286208</pub-id></element-citation></ref></ref-list></back></article>